3SBio Inc. (HKG:1530)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
25.38
+0.06 (0.24%)
Apr 2, 2026, 4:08 PM HKT
Market Cap63.39B +199.1%
Revenue (ttm)19.69B +94.3%
Net Income9.44B +305.8%
EPS3.82 +303.6%
Shares Out2.50B
PE Ratio6.65
Forward PE20.33
Dividend0.25 (0.99%)
Ex-Dividend DateJul 21, 2026
Volume57,285,612
Average Volume34,082,571
Open25.40
Previous Close25.32
Day's Range24.72 - 26.20
52-Week Range10.00 - 36.80
Beta0.59
RSI60.80
Earnings DateMar 30, 2026

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 6,268
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1530
Full Company Profile

Financial Performance

In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.

Financial numbers in CNY Financial Statements